Medical cannabis authorization patterns, safety, and associated effects in older adults
Open Access
- 22 September 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Cannabis Research
- Vol. 4 (1), 1-10
- https://doi.org/10.1186/s42238-022-00158-5
Abstract
Use of medical cannabis is increasing among older adults. However, few investigations have examined cannabis use in this population. We assessed the authorization patterns, safety, and effects of medical cannabis in a sub-analysis of 201 older adults (aged ≥ 65 years) who completed a 3-month follow-up during this observational study of patients who were legally authorized a medical cannabis product (N = 67). Cannabis authorization patterns, adverse events (AEs), Edmonton Symptom Assessment Scale-revised (ESAS-r), and Brief Pain Inventory Short Form (BPI-SF) data were collected. The most common symptoms for which medical cannabis was authorized were pain (159, 85.0%) and insomnia (9, 4.8%). At baseline and at the 3-month follow-up, cannabidiol (CBD)-dominant products were authorized most frequently (99, 54%), followed by balanced products (76, 42%), and then delta-9-tetrahydrocannabinol (THC)-dominant products (8, 4.4%). The most frequent AEs were dizziness (18.2%), nausea (9.1%), dry mouth (9.1%), and tinnitus (9.1%). Significant reductions in ESAS-r scores were observed over time in the domains of drowsiness (p = .013) and tiredness (p = .031), but not pain (p = .106) or well-being (p = .274). Significant reductions in BPI-SF scores over time were observed for worst pain (p = .010), average pain (p = .012), and overall pain severity (p = 0.009), but not pain right now (p = .052) or least pain (p = .141). Overall, results suggest medical cannabis was safe, well-tolerated, and associated with clinically meaningful reductions in pain in this sample of older adults. However, the potential bias introduced by the high subject attrition rate means that all findings should be interpreted cautiously and confirmed by more rigorous studies.Keywords
Funding Information
- Canopy Growth Corporation
This publication has 37 references indexed in Scilit:
- Role of the endocannabinoid system in diabetes and diabetic complicationsBritish Journal of Pharmacology, 2015
- Cannabinoids for Medical UseJAMA, 2015
- Endocannabinoid signaling at the periphery: 50 years after THCTrends in Pharmacological Sciences, 2015
- Cannabis in medicine: a national educational needs assessment among Canadian physicians.BMC Medical Education, 2015
- The Role of the Endocannabinoid System in PainHandbook of Experimental Pharmacology, 2015
- Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis usersThe American Journal of Drug and Alcohol Abuse, 2013
- A Multicenter Study Comparing Two Numerical Versions of the Edmonton Symptom Assessment System in Palliative Care PatientsJournal of Pain and Symptom Management, 2011
- Adverse effects of medical cannabinoids: a systematic reviewCMAJ : Canadian Medical Association Journal, 2008
- Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT RecommendationsThe Journal of Pain, 2008
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008